Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Portfolio Pulse from Avi Kapoor
Several top Wall Street analysts have updated their price targets and ratings for various companies. Notable changes include Nomura's downgrade of Uber from Buy to Neutral with a price target increase, Goldman Sachs' price target raise for Equifax while maintaining a Neutral rating, and Ascendiant Capital's price target increases for Expedia, Booking Holdings, and Outlook Therapeutics with maintained Buy ratings. Other firms like BTIG, Raymond James, TD Cowen, Benchmark, and Mizuho also adjusted their price targets for Natera, ConocoPhillips, NeoGenomics, Altice USA, and ACADIA Pharmaceuticals, respectively.
December 29, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho raised ACADIA Pharmaceuticals' price target from $35 to $40 and maintained a Buy rating. The stock declined by 1.2% to $31.39.
The increased price target and positive rating could indicate potential for stock recovery and growth in the short term.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Benchmark slashed Altice USA's price target from $10 to $5 but maintained a Buy rating. Altice USA's shares surged by 6.6% to $3.25.
The drastic price target cut contrasts with the Buy rating and the stock's recent surge, indicating uncertainty in the short-term direction.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ascendiant Capital raised Booking Holdings' price target from $3,700 to $3,900 with a Buy rating. Booking's shares increased by 0.5% to $3,550.47.
The raised price target and positive rating suggest continued confidence from analysts, which could lead to further stock appreciation.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ascendiant Capital increased Expedia's price target from $133 to $168 and maintained a Buy rating. Expedia's stock saw a marginal gain of 0.02% to $153.28.
The significant price target increase and maintained Buy rating could positively influence investor sentiment and stock performance in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
BTIG increased Natera's price target from $75 to $85 and kept a Buy rating. Natera's stock rose by 1.3% to $62.04.
The price target hike and Buy rating could contribute to positive momentum for Natera's stock in the short term.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
NEUTRAL IMPACT
Raymond James reduced ConocoPhillips' price target from $146 to $140 but maintained a Strong Buy rating. The stock fell by 1.7% to $116.50.
Despite the price target cut, the Strong Buy rating indicates continued analyst confidence, which may balance the short-term impact on the stock.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Goldman Sachs raised Equifax's price target from $195 to $222 while maintaining a Neutral rating. Equifax's shares dropped by 0.3% to $249.61.
The price target increase is positive, but the Neutral rating and the stock's slight decline indicate a balanced short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Ascendiant Capital raised Outlook Therapeutics' price target from $1.5 to $2 and maintained a Buy rating. The stock fell by 7.8% to $0.4267.
The price target increase suggests optimism from analysts, but the significant stock drop may reflect current negative investor sentiment.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85
NEUTRAL IMPACT
Nomura downgraded Uber from Buy to Neutral but increased the price target from $59 to $62. Uber's stock slightly declined by 0.2% to close at $63.14.
The downgrade to Neutral suggests a more cautious outlook despite the price target increase, which could lead to mixed investor sentiment in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
TD Cowen lowered NeoGenomics' price target from $22 to $19 while maintaining an Outperform rating. The stock plummeted by 18.1% to $16.79.
The significant stock drop and reduced price target suggest negative market sentiment, despite the Outperform rating.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90